- Home
- IBCP vs SION Comparison
IBCP vs SION Comparison
Compare IBCP & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- SION
- Stock Information
- Founded
- IBCP 1864
- SION 2019
- Country
- IBCP United States
- SION United States
- Employees
- IBCP N/A
- SION N/A
- Industry
- IBCP Major Banks
- SION
- Sector
- IBCP Finance
- SION
- Exchange
- IBCP Nasdaq
- SION NYSE
- Market Cap
- IBCP 630.0M
- SION 338.0M
- IPO Year
- IBCP N/A
- SION 2025
- Fundamental
- Price
- IBCP $31.88
- SION $12.57
- Analyst Decision
- IBCP Hold
- SION Strong Buy
- Analyst Count
- IBCP 3
- SION 1
- Target Price
- IBCP $36.67
- SION $32.00
- AVG Volume (30 Days)
- IBCP 113.9K
- SION 128.6K
- Earning Date
- IBCP 04-24-2025
- SION 05-25-2025
- Dividend Yield
- IBCP 3.25%
- SION N/A
- EPS Growth
- IBCP 6.78
- SION N/A
- EPS
- IBCP 3.14
- SION N/A
- Revenue
- IBCP $219,516,000.00
- SION N/A
- Revenue This Year
- IBCP N/A
- SION N/A
- Revenue Next Year
- IBCP $6.51
- SION N/A
- P/E Ratio
- IBCP $10.19
- SION N/A
- Revenue Growth
- IBCP 6.57
- SION N/A
- 52 Week Low
- IBCP $22.53
- SION $7.26
- 52 Week High
- IBCP $40.32
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- IBCP 60.04
- SION N/A
- Support Level
- IBCP $30.76
- SION N/A
- Resistance Level
- IBCP $31.72
- SION N/A
- Average True Range (ATR)
- IBCP 0.87
- SION 0.00
- MACD
- IBCP 0.19
- SION 0.00
- Stochastic Oscillator
- IBCP 91.90
- SION 0.00
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.